Office Action 2: Notice of Allowance (2025-02-12)

CLAIMS:
LISTING OF THE CLAIMS:

This listing of the claims is provided for the Examiner's convenience. No amendments are made.

1\. - 87. (Canceled)286

88\. (Previously Presented) A method of treating pneumonia associated with COVID-19 comprising administering to a human subject in need thereof an effective amount of an anti-LIGHT antibody comprising a heavy chain and a light chain variable region comprising a CDR-H 1 having the sequence of SEQ ID NO: 2, CDR-H2 having the sequence of SEQ ID NO: 3, CDR-H3 having the sequence of SEQ ID NO: 4, CDR-L1 having the sequence of SEQ ID NO: 5, CDR-L2 having the sequence of SEQ ID NO: 6,and CDR-L3 having the sequence of SEQ ID NO: 7.

89\. (Previously Presented) The method of claim 88, wherein administration of the anti- LIGHT antibody reduces serum free-LIGHT levels in the subject.

90\. (Previously Presented) The method of claim 88, wherein a single dose of about 16 mg/kg of the anti-LIGHT antibody is administered.

91\. (Previously Presented) The method of claim 88, wherein the subject has received, or is currently receiving, an anti-COVID-19 therapy comprising a corticosteroid and/or remdesivir.

92\. (Previously Presented) The method of claim 88, wherein administration of the anti- LIGHT antibody reduces the subject's risk of mortality by equal to or greater than 50% at 28 days and/or 60 days after administration.

93\. (Previously Presented) The method of claim 88, where the subject is 60 years of age or older.

94\. (Previously Presented) The method of claim 88, wherein administration of the anti- LIGHT antibody reduces the subject's risk of respiratory failure.

95\. (Previously Presented) A method of treating respiratory failure associated with COVID- 19 pneumonia comprising administering to a human subject in need thereof an effective amount of an anti-LIGHT antibody comprising a heavy chain and a light chain variable region comprising a CDR-H1 having the sequence of SEQ ID NO: 2, CDR-H2 having the sequence of SEQ ID NO: 3, CDR-H3 having the sequence of SEQ ID NO: 4, CDR- -3-

having the sequence of SEQ ID NO: 5, CDR-L2 having the sequence of SEQ ID 6, and CDR-L3 having the sequence of SEQ ID NO: 7. 0

OFFICE ACTION:
EXAMINER’S AMENDMENT
Notice of Pre-AIA  or AIA  Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
An examiner’s amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.
In the specification:
Amend the title to the following –
METHODS OF TREATING PNEUMONIA OR RESPIRATORY FAILURE ASSOCIATED WITH COVID-19 BY ADMINISTERING AN ANTI-LIGHT ANTIBODY
Advisory information

APPLICANT REBUTTAL: 
REMARKS
Status of the Claims
Claims 88-95 are pending in the application. Claims 1-87 were previously canceled without prejudice or disclaimer.
Specification
The specification has been amended to change the application type from a divisional application to a continuation application. A corrected application data sheet is filed herewith reflecting this change. The amendments add no new matter.
Double Patenting
Claims 88-95 stand rejected on the ground of nonstatutory double patenting as allegedly being unpatentable over claims 1-10 of U.S. Patent No. 11,708,406. Action at page 4.
Without conceding in the basis of rejection, and solely to expedite the prosecution of this application, Applicant submits herewith a terminal disclaimer over U.S. Patent No. 11,708,406. As such, Applicant respectfully requests that the double patenting rejection of claims 88-95 be withdrawn.
Conclusion